BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 16777629)

  • 1. [Prognostic factors for febrile neutropenia].
    Ray-Coquard I; Borg C; Bachelot T; Fayette J; Zufferey L; Guastalla JP; Ghesquière H; Blay JY; Sebban C; Marec-Bérard P; Biron P
    Bull Cancer; 2006 May; 93(5):501-6. PubMed ID: 16777629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management.
    Crawford J; Dale DC; Lyman GH
    Cancer; 2004 Jan; 100(2):228-37. PubMed ID: 14716755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
    Timmer-Bonte JN; Tjan-Heijnen VC
    Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The economics of the colony-stimulating factors in the prevention and treatment of febrile neutropenia.
    Lyman GH; Kuderer NM
    Crit Rev Oncol Hematol; 2004 May; 50(2):129-46. PubMed ID: 15157662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
    Bobey N; Woodman RC
    Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Chemotherapy-induced febrile neutropenia: about 200 episodes. Clinical, microbiological and therapeutic characteristics].
    Gharbi O; Ben Hadj Hassen S; Kaabia N; Limam S; Hadj Amor M; Ben Fatma L; Landolsi A; Hochlef M; Letaief A; Boukadida J; Ben Ahmed S
    Pathol Biol (Paris); 2008 May; 56(3):154-7. PubMed ID: 18178025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Granulocyte colony-stimulating factors: finding the right indication.
    Lyman GH; Shayne M
    Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prevention of febrile neutropenia.
    Pascoe J; Cullen M
    Curr Opin Oncol; 2006 Jul; 18(4):325-9. PubMed ID: 16721125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
    Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
    J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of myeloid growth factors in cancer chemotherapy.
    Lyman GH; Kuderer NM
    Curr Hematol Rep; 2003 Nov; 2(6):471-9. PubMed ID: 14561391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimizing the management of chemotherapy-induced neutropenia.
    Dale DC
    Clin Adv Hematol Oncol; 2003 Nov; 1(11):679-84. PubMed ID: 16258470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Granulocyte colony-stimulating factors in the management of chemotherapy-induced neutropenia: evidence based review.
    Bhana N
    Curr Opin Oncol; 2007 Jul; 19(4):328-35. PubMed ID: 17545795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. G-CSF in the prevention of febrile neutropenia in chemotherapy in breast cancer patients.
    Krol J; Paepke S; Jacobs VR; Paepke D; Euler U; Kiechle M; Harbeck N
    Onkologie; 2006 Apr; 29(4):171-8. PubMed ID: 16601374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte colony-stimulating factor use in patients with chemotherapy-induced neutropenia: clinical and economic benefits.
    Rader M
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):16-21. PubMed ID: 16736984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemotherapy-induced neutropenia in lung cancer patients: the role of antibiotic prophylaxis.
    Kouranos V; Dimopoulos G; Vassias A; Syrigos KN
    Cancer Lett; 2011 Dec; 313(1):9-14. PubMed ID: 21955615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity.
    Johnston EM; Crawford J
    Semin Oncol; 1998 Oct; 25(5):552-61. PubMed ID: 9783594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Guidelines for prevention of febrile neutropenia].
    Barroso S; Damasceno M; Dinis J; Gervásio H; da Luz R; Passos-Coelho JL; Sá A; Costa L; Rodrigues H; Andrade S; Macedo A; Moital I
    Acta Med Port; 2008; 21(1):7-19. PubMed ID: 18489831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
    Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
    Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.